34570-17-7

Basic information

• Product Name: MALONAMAMIDINE HYDROCHLORIDE
• Synonyms: 3-AMINO-1-IMINO-3-OXO-1-PROPANAMINIUM CHLORIDE;3-AMINO-3-IMINOPROPANAMIDE HYDROCHLORIDE;MALONAMAMIDINE HYDROCHLORIDE;amidinomalonamide hydrochloride;MALONAMAMIDINE HYDROCHLORIDE 99%;MalonamamidineHCl;Malonamamidinehydrochloride,98+%;α-Amidinoacetylamine hydrochloride
• CAS NO: 34570-17-7
• Molecular Formula: C₃H₇N₃O*ClH
• Molecular Weight: 137.57
• EINECS: 252-095-5
• Product Categories: Imines/Amidines;Nitrogen Compounds;Organic Building Blocks
• Mol File: 34570-17-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 174-176 °C(lit.)
• Boiling Point: 315.4 °C at 760 mmHg
• Flash Point: 144.6 °C
• Appearance: White to yellowish crystalline powder
• Vapor Pressure: 0.000437mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: MALONAMAMIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: MALONAMAMIDINE HYDROCHLORIDE(34570-17-7)
• EPA Substance Registry System: MALONAMAMIDINE HYDROCHLORIDE(34570-17-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 34570-17-7(Hazardous Substances Data)

Usage

Description

Malonamamidine hydrochloride is a white to yellowish crystalline powder with unique chemical properties. It is a compound that has been utilized in various chemical and pharmaceutical applications due to its specific characteristics.

Uses

Used in Pharmaceutical Industry:
Malonamamidine hydrochloride is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the formation of complex molecular structures.
Specifically, it is used as a key component in the preparation of 2-Amino-4,6-dimethyl nicotinamide, which is an important compound in the development of medications targeting specific health conditions.

InChI:InChI=1/C3H7N3O/c4-2(5)1-3(6)7/h1H2,(H3,4,5)(H2,6,7)/p+1

Upstream product

• 170749-59-4 1-benzhydrylazetidin-3-yl 3-amino-3-iminopropanoate acetate 
• 27317-59-5 Ethyl 3-ethoxy-3-iminopropionate 
• 2318-25-4 ethyl 3-ethoxy-3-iminopropanoate hydrochloride 

Downstream Products

• 13438-65-8 2-aminopyridine-3-carboxamide 
• 1513-70-8 6-amino-4-hydroxy-2-trifluoromethylpyrimidine 
• 7144-20-9 2-Amino-4,6-dimethylnicotinamide 
• 6285-64-9 phenylazomalonamamidine hydrochloride 
• 79823-36-2 2-Amino-5-methyl-4-phenyl-3-pyrrolcarboxamid 
• 21417-20-9 Chinazolin-4-on-2-yl-essigsaeureamid 
• 1052080-54-2 2-Amino-5-(4-fluoro-2-methoxyphenyl)pyrrole-3-carboxamide 
• 1052081-49-8 2-Amino-5-(4-bromophenyl)-4-methylpyrrole-3-carboxamide 
• 1052080-53-1 2-amino-5-(4-bromophenyl)pyrrole-3-carboxamide 
• 28215-45-4 2-(4,6-dihydroxypyrimidin-2-yl)acetamide 

Relevant articles and documents

Azelnidipine impurity and preparation method thereof

The invention belongs to the field of preparation of azelnidipine impurities, and discloses an azelnidipine impurity and a preparation method thereof. According to the method, a key intermediate of azelnidipine is taken as a raw material, organic ammonium salt and an organic aluminon reagent are subjected to ammonolysis to obtain malonyl amidine salt, the malonyl amidine salt and the key intermediate of the azelnidipine are subjected to Hantzsch condensation, and the high-purity azelnidipin ammonolysis impurity is obtained after oriented synthesis. The preparation method has the advantages ofmild reaction condition, simplicity and easiness in operation, easiness in separation of target products, and high yield and purity of the products. After the obtained azelnidipine impurity is determined, the accurate content of the azelnidipine impurity in crude drugs can be reflected accurately; the known impurity can be composited into an impurity comparison product in an oriented way, the accurate content of the impurity in the crude drugs can be calculated according to an external standard method and the like, and the azelnidipine impurity has positive significance in purity control of the crude drugs.

Xanthine oxidase (XO): Relative configuration of complexes formed by the enzyme, 2- or 8-N-alkylhypoxanthines and 2-N-alkyl-8-azahypoxanthines. XII

Several 2- or 8-n-alkyl-hypoxanthines and a 2,8-di-n-pentylhypoxanthine were synthesized and tested as substrates or inhibitors of Xanthine Oxidase (XO). 8-Alkyl derivatives showed a substrate behaviour, whereas 2-alkyl substituted compounds were non-substrates and inhibitors. 2,8-di-n-pentylhypoxanthine was ineffective as inhibitor. The comparison between their activity allowed us to conclude that the complexes formed by the enzyme and the cited n-alkylhypoxanthines or 2-n -alkyl-8-azahypoxanthines involve their N(3) and N(9) positions in all the cases. The position of the n-alkyl chain determines the disposition of the molecule inside the complex: 2-n-alkyl-hypoxanthines and 2-n-alkyl-8-azahypoxanthines gave complexes with the same orientation of heterocyclic moieties, opposite that given by 8-n-alkyl-hypoxanthines.

Inhibitors of the advanced glycosylation of proteins and methods of use therefor

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylatin. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.